NASDAQ:PCSA
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. reported net income of −$13.6M in fiscal 2025. The diluted share count rose 969.3%.Summary generated from Processa Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−373.0%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+969.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | n/a | n/a | n/a |
| Operating income | −12 | −28 | −11 | −12 | −14 |
| Net income | −11 | −27 | −11 | −12 | −14 |
| Free cash flow | n/a | n/a | −8 | −11 | n/a |
Recent filings
- 8-K/AAmended other events
Oct 5, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 4Insider transaction report
Aug 11, 2026 - 8-KDirector or officer change
Aug 4, 2026 - 4Insider transaction report
Jul 30, 2026 - 8-KEntry into a material agreement
Jul 29, 2026 - DEF 14AProxy statement
Jun 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026